MIcrovascular dysfuNction In Moderate-severe Psoriasis
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Psoriasis, a common chronic inflammatory skin disease affecting approximately 2% of the
population, is associated with increased cardiovascular (CV) risk. Despite the implication of
inflammation in this excess risk, it remains unclear whether reducing inflammation reduces
the risk of cardiac events. This study proposes to test whether Tildrakizumab, an FDA
approved therapy for psoriasis that blocks IL-23 and the Th17 pathway of inflammation,
improves coronary vascular function and coronary flow reserve, as measured by noninvasive
imaging with cardiac positron emission tomography. In so doing, improvement in coronary
vasoreactivity, endothelial function, and tissue perfusion may have beneficial effects on
myocardial mechanics, left ventricular deformation and function and, ultimately, symptoms and
prognosis.
This research may offer novel insights into the contributors of CV risk in psoriasis and
provide data to support the development of strategies to prevent cardiovascular events in
psoriatic disease.